- Home
- SF vs ROIV Comparison
SF vs ROIV Comparison
Compare SF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- ROIV
- Stock Information
- Founded
- SF 1890
- ROIV 2014
- Country
- SF United States
- ROIV United Kingdom
- Employees
- SF N/A
- ROIV N/A
- Industry
- SF Investment Bankers/Brokers/Service
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SF Finance
- ROIV Health Care
- Exchange
- SF Nasdaq
- ROIV Nasdaq
- Market Cap
- SF 9.8B
- ROIV 8.1B
- IPO Year
- SF N/A
- ROIV N/A
- Fundamental
- Price
- SF $114.20
- ROIV $12.39
- Analyst Decision
- SF Buy
- ROIV Strong Buy
- Analyst Count
- SF 8
- ROIV 4
- Target Price
- SF $114.88
- ROIV $15.50
- AVG Volume (30 Days)
- SF 644.9K
- ROIV 4.8M
- Earning Date
- SF 10-22-2025
- ROIV 08-11-2025
- Dividend Yield
- SF 1.60%
- ROIV N/A
- EPS Growth
- SF 9.88
- ROIV N/A
- EPS
- SF 5.17
- ROIV N/A
- Revenue
- SF $5,091,577,000.00
- ROIV $23,233,000.00
- Revenue This Year
- SF $10.70
- ROIV N/A
- Revenue Next Year
- SF $12.22
- ROIV $281.14
- P/E Ratio
- SF $22.30
- ROIV N/A
- Revenue Growth
- SF 11.86
- ROIV N/A
- 52 Week Low
- SF $73.27
- ROIV $8.73
- 52 Week High
- SF $120.64
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- SF 54.43
- ROIV 66.14
- Support Level
- SF $109.73
- ROIV $11.85
- Resistance Level
- SF $117.49
- ROIV $12.18
- Average True Range (ATR)
- SF 2.10
- ROIV 0.28
- MACD
- SF -0.12
- ROIV 0.04
- Stochastic Oscillator
- SF 57.60
- ROIV 91.89
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.